Skip to main content

Roche Coronavirus test gets FDA approval

| News

Roche Coronavirus test gets FDA approval


The US regulatory authority has authorized a test developed by the Basel-based pharmaceutical company Roche to detect the SARS-CoV 2 virus. Due to Roche’s work, numerous additional tests can be carried out in the USA, and for this reason Roche received the express thanks of President Trump.

Roche logo on building (Img: Roche)

The Food and Drug Administration (FDA) has authorized the cobas SARS-CoV-2 test developed by Roche on an emergency use basis, as detailed in a press release issued by the Basel-based pharmaceutical company. The coronavirus test will therefore be available in all markets that accept the CE mark.

The Roche test will allow the number of tests to check whether a person has been infected with the coronavirus in the USA to be significantly increased. In remarks made by Donald Trump, the US President commented: “I want to thank Roche, a great company, for their incredible work”. This will allow an additional 1.4 million tests to be carried out in the near future, with an additional 5 million tests even possible within a month, Trump explained. In addition to praising Roche, the President also expressed thanks to Thermo Fisher.

In order to carry out the coronavirus tests developed by Roche, hospitals and laboratories require either of the cobas 6800 or cobas 8800 automated systems. These are widespread in the USA and around the world, according to Roche. The comprehensive testing capacities that are now available will allow rapid, effective reactions to combat this pandemic, explains Thomas Schinecker, CEO of Roche Diagnostics, in the press release. With cobas 6800/8800, a total of 96 tests can be analyzed within the space of three hours. Extra test stations increase this number further still. With cobas SARS-CoV-2, the results of the coronavirus tests are available within three-and-a-half hours, Roche states.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.